Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
|
|
Sucampo Pharmaceuticals, Inc. (SCMP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/23/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 02/16/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/16/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/16/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/16/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/15/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/15/2018 |
SC 13D/A
| Ueno Ryuji reports a 0% stake in Sucampo Pharmaceuticals, Inc. |
| 02/14/2018 |
4
| Kuno Sachiko (10% Owner) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Gifted 2,000,000 shares
@ $0
Unknown transaction of 5,137,344 shares
@ $18, valued at
$92.5M
|
|
| 02/14/2018 |
4
| Ueno Ryuji (10% Owner) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Gifted 600,000 shares
@ $0
Gifted 2,000,000 shares
@ $0
Unknown transaction of 5,406,585 shares
@ $18, valued at
$97.3M
|
|
| 02/13/2018 |
4
| OCONNELL MAUREEN (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 5,130 shares
@ $18, valued at
$92.3k
Disposed/sold 30,000 options to buy
@ $5.19, valued at
$155.7k
Disposed/sold 20,000 options to buy
@ $8.62, valued at
$172.4k
Disposed/sold 20,000 options to buy
@ $6.8, valued at
$136k
Disposed/sold 20,000 options to buy
@ $16.23, valued at
$324.6k
Disposed/sold 10,000 options to buy
@ $10.3, valued at
$103k
|
|
| 02/13/2018 |
4
| Walbert Timothy P (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 5,130 shares
@ $18, valued at
$92.3k
Disposed/sold 10,000 options to buy
@ $10.3, valued at
$103k
|
|
| 02/13/2018 |
4
| Spiegel Robert J. (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 5,130 shares
@ $18, valued at
$92.3k
Disposed/sold 30,000 options to buy
@ $14.04, valued at
$421.2k
Disposed/sold 20,000 options to buy
@ $16.23, valued at
$324.6k
Disposed/sold 10,000 options to buy
@ $10.3, valued at
$103k
|
|
| 02/13/2018 |
4
| Smith Karen L. (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 30,000 options to buy
@ $10.95, valued at
$328.5k
|
|
| 02/13/2018 |
4
| Edick Paul R (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 14,930 shares
@ $18, valued at
$268.7k
Disposed/sold 10,000 options to buy
@ $10.3, valued at
$103k
|
|
| 02/13/2018 |
4
| Donley Matthew Maxwell (EVP, Global HR, IT & Strategy) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Granted 36,975 shares
@ $18, valued at
$665.6k
Disposed/sold 150,000 options to buy
@ $7.4, valued at
$1.1M
Disposed/sold 25,000 options to buy
@ $6.75, valued at
$168.8k
Disposed/sold 28,000 options to buy
@ $14.82, valued at
$415k
Disposed/sold 75,000 options to buy
@ $13.8, valued at
$1M
Disposed/sold 101,000 options to buy
@ $11.85, valued at
$1.2M
|
|
| 02/13/2018 |
4
| Greenleaf Peter (CEO) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 129,729 shares
@ $18, valued at
$2.3M
Disposed/sold 600,000 options to buy
@ $8.49, valued at
$5.1M
Disposed/sold 200,000 options to buy
@ $5.9, valued at
$1.2M
Disposed/sold 210,000 options to buy
@ $14.82, valued at
$3.1M
Disposed/sold 420,000 options to buy
@ $13.8, valued at
$5.8M
Disposed/sold 237,000 options to buy
@ $11.85, valued at
$2.8M
|
|
| 02/13/2018 |
4
| JOHNSON JOHN (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 5,130 shares
@ $18, valued at
$92.3k
Disposed/sold 30,000 options to buy
@ $13.92, valued at
$417.6k
Disposed/sold 20,000 options to buy
@ $16.23, valued at
$324.6k
Disposed/sold 10,000 options to buy
@ $10.3, valued at
$103k
|
|
| 02/13/2018 |
4
| Kiener Peter A (Chief Science Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 44,856 shares
@ $18, valued at
$807.4k
Disposed/sold 250,000 options to buy
@ $8.33, valued at
$2.1M
Disposed/sold 38,500 options to buy
@ $14.82, valued at
$570.6k
Disposed/sold 87,203 options to buy
@ $13.8, valued at
$1.2M
Disposed/sold 133,000 options to buy
@ $11.85, valued at
$1.6M
|
|
| 02/13/2018 |
4
| Lichtlen Peter (Chief Medical Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 24,000 shares
@ $18, valued at
$432k
Disposed/sold 78,200 options to buy
@ $4.27, valued at
$333.9k
Disposed/sold 78,200 options to buy
@ $7.17, valued at
$560.7k
Disposed/sold 25,000 options to buy
@ $6.75, valued at
$168.8k
Disposed/sold 44,000 options to buy
@ $14.82, valued at
$652.1k
Disposed/sold 44,000 options to buy
@ $13.8, valued at
$607.2k
Disposed/sold 45,000 options to buy
@ $11.85, valued at
$533.3k
|
|
| 02/13/2018 |
4
| PFREUNDSCHUH PETER P. (CFO) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 263 shares
@ $18, valued at
$4.7k
Disposed/sold 150,000 options to buy
@ $10.9, valued at
$1.6M
|
|
| 02/13/2018 |
4
| Bryan Jones W. (Sr. Vice Pres., BD & Licensing) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 5,139 shares
@ $18, valued at
$92.5k
Disposed/sold 150,000 options to buy
@ $10.9, valued at
$1.6M
|
|
| 02/13/2018 |
4
| Meyenburg Jason Patrick (Chief Commercial Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 30,228 shares
@ $18, valued at
$544.1k
Disposed/sold 150,000 options to buy
@ $10.65, valued at
$1.6M
|
|
| 02/13/2018 |
4
| Driggs Alex (General Counsel & Corp. Sec.) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 6,084 shares
@ $18, valued at
$109.5k
Disposed/sold 25,600 options to buy
@ $16.04, valued at
$410.6k
Disposed/sold 24,150 options to buy
@ $13.8, valued at
$333.3k
Disposed/sold 11,068 options to buy
@ $11.85, valued at
$131.2k
|
|
| 02/13/2018 |
SC 13G/A
| ING GROEP NV reports a 0% stake in Sucampo Pharmaceuticals, Inc. |
| 02/13/2018 |
SC 13G
| LSV ASSET MANAGEMENT reports a 5.3% stake in SUCAMPO PHARMACEUTICALS, INC. |
| 02/13/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/13/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 02/13/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/13/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/13/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/13/2018 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 02/13/2018 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 02/13/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/13/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
|
|
|